Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting

– CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability – CR rate of 44% in subjects treated with Annamycin (n=9) – Durability of CR’s up to 8 months & climbing (no relapses to date) – Recruitment in MB-106 Phase 1B/2 clinical trial reaches 59% – Announces Publication for 65th ASH Annual Meeting and Exposition – Annamycin continues to be 100% non-cardiotoxic HOUSTON, Dec. 11, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Company’s ongoing European Phase 1B/2 clinical trial evaluating Annamycin for the treatment of acute myeloid leukemia or AML (MB-106) to key opinion leaders and current investigators at a meeting held in conjunction with the 65th American Society of Hematology Meeting and Exposition (ASH) in San Diego on December 10, 2023. Additionally, the Company will have a paper published on its MB-106 clinical trial as part of ASH. A link will be provided on the Company’s website once this publication is available online.

The release as fetched from its publisher. moleculin.com ↗